Abstract 98P
Background
Lung cancer represents the leading cause of cancer-related death worldwide, with non-small cell lung cancer (NSCLC) accounting for ∼85% of total cases. Although immunotherapy using immune checkpoint inhibitors (ICI) has shown promising results, only a subset of patients benefits from it and there is an urgent need for reliable predictive response biomarkers. Furthermore, traditional tissue biopsies are limited in size and provide a biased representation of the tumour. Therefore, we aimed to explore the possibility to obtain predictive biomarkers of response to ICI in a non-invasive way using liquid biopsy (LB).
Methods
To counter this, we analysed samples from 25 patients from advanced NSCLC treated with pembrolizumab at first line. Blood and tissue samples were collected at baseline to obtain cell-free DNA (cfDNA) and genomic DNA from plasma and PBMCs respectively, and tumour DNA from FFPE primary tumour. All samples underwent a target NGS panel to call somatic mutations in circulating tumour DNA (ctDNA) and primary tumour, evaluating their potential as predictive biomarkers.
Results
Through the integration of three different bioinformatic approaches for variant calling and ROC curve analysis, we identified mutations in key cancer-related genes associated with a 3-month radiological response. We also assessed a promising mutational signature in ctDNA comprising 10 genes with a high ability to predict response to ICI (AUC = 0.98). Although we explored copy number alterations and tumour mutational burden in LB, results did not yield statistical significance, suggesting that assessment of point mutations in particular genes and the proposed signature hold higher potential as biomarkers. Moreover, we compared ctDNA analysis with tissue biopsies, revealing a high concordance between ctDNA and primary tumour, enhancing the reliability of ctDNA analysis as a good alternative for tumour assessment.
Conclusions
These findings highlight the value of ctDNA analysis as a non-invasive predictive biomarker for ICI response and its correlation with mutations found in primary tumours. We also proposed a mutational signature to predict response at baseline for advanced NSCLC ICI treated patients, which could be readily implemented in the clinical management of the disease.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Translational Molecular Oncology Unit. IIS Galicia Sur.
Funding
Vigo Contra el Cáncer; GAIN; Xunta de Galicia (ED481A-2020/214); Miguel Servet program (CP20/00188).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract